Zebrafish (Danio rerio) embryo as a platform for the identification of novel angiogenesis inhibitors of retinal vascular diseases

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 7, 2016, Pages 1291-1296

  Rezzola, Sara ^a   Paganini, Giuseppe ^a   Semeraro, Francesco ^a   Presta, Marco ^a   Tobia, Chiara ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Angiogenesis; Angiogenesis inhibitors; Embryonic development; Vascular retina diseases; Zebrafish

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BLINDNESS; EMBRYO DEVELOPMENT; HUMAN; NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; REVIEW; ZEBRA FISH;

EID: 84963945580     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.04.009     Document Type: Review

References (50)

1. Congdon N., et al. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 2004, 122(4):477-485. 10.1001/archopht.122.4.477.
2. Campochiaro P.A. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog. Retin. Eye Res. 2015, 49:67-81. 10.1016/j.preteyeres.2015.06.002.
3. Miller J.W., et al. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013, 120(1):106-114. 10.1016/j.ophtha.2012.07.038.
4. Kwong T.Q., Mohamed M. Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. Br. J. Clin. Pharmacol. 2014, 78(4):699-706. 10.1111/bcp.12371.
5. Cai X., Sezate S.A., McGinnis J.F. Neovascularization: ocular diseases, animal models and therapies. Adv. Exp. Med. Biol. 2012, 723:245-252. 10.1007/978-1-4614-0631-0_32.
6. Stahl A., et al. The mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 2010, 51(6):2813-2826. 10.1167/iovs.10-5176.
7. Wells D.J. Animal welfare and the 3Rs in European biomedical research. Ann. N. Y. Acad. Sci. 2011, 1245:14-16. 10.1111/j.1749-6632.2011.06335.x.
8. Rezzola S., et al. In vitro and ex vivo retina angiogenesis assays. Angiogenesis 2014, 17(3):429-442. 10.1007/s10456-013-9398-x.
9. Schuermann A., Helker C.S., Herzog W. Angiogenesis in zebrafish. Semin. Cell Dev. Biol. 2014, 31:106-114. 10.1016/j.semcdb.2014.04.037.
10. Tobia C., De Sena G., Presta M. Zebrafish embryo, a tool to study tumor angiogenesis. Int. J. Dev. Biol. 2011, 55(4-5):505-509.
11. Kitambi S.S., et al. Small molecule screen for compounds that affect vascular development in the zebrafish retina. Mech. Dev. 2009, 126(5-6):464-477.
12. Chen J., Smith L.E. Retinopathy of prematurity. Angiogenesis 2007, 10(2):133-140. 10.1007/s10456-007-9066-0.
13. Fleck B.W. Management of retinopathy of prematurity. Arch. Dis. Child. Fetal Neonatal Ed. 2013, 98(5):F454-F456. 10.1136/archdischild-2013-303933.
14. Stitt A.W., et al. The progress in understanding and treatment of diabetic retinopathy. Prog. Retin. Eye Res. 2016, 51:156-186. 10.1016/j.preteyeres.2015.08.001.
15. Semeraro F., et al. Diabetic retinopathy: vascular and inflammatory disease. J. Diabetes Res. 2015, 2015:582060. 10.1155/2015/582060.
16. Shao J., Choudhary M.M., Schachat A.P. Neovascular age-related macular degeneration. Dev. Ophthalmol. 2015, 55:125-136. 10.1159/000438969.
17. Edwards A.O., Malek G. Molecular genetics of AMD and current animal models. Angiogenesis 2007, 10(2):119-132. 10.1007/s10456-007-9064-2.
18. MacDonald D. The ABCs of RVO: a review of retinal venous occlusion. Clin. Exp. Optom. 2014, 97(4):311-323. 10.1111/cxo.12120.
19. Wang S., Park J.K., Duh E.J. Novel targets against retinal angiogenesis in diabetic retinopathy. Curr. Diab. Rep. 2012, 12(4):355-363. 10.1007/s11892-012-0289-0.
20. Rezzola S., et al. Therapeutic Potential of Anti-Angiogenic Multitarget N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy. Diabetes 2015, 64(7):2581-2592. 10.2337/db14-1378.
21. Dal Monte M., et al. Antiangiogenic effectiveness of the urokinase receptor-derived peptide UPARANT in a model of oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2015, 56(4):2392-2407. 10.1167/iovs.14-16323.
22. Lawson N.D., Wolfe S.A. Forward and reverse genetic approaches for the analysis of vertebrate development in the zebrafish. Dev. Cell 2011, 21(1):48-64. 10.1016/j.devcel.2011.06.007.
23. Pichler F.B., et al. Chemical discovery and global gene expression analysis in zebrafish. Nat. Biotechnol. 2003, 21(8):879-883. 10.1038/nbt852.
24. Bruni G., Lakhani P., Kokel D. Discovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish. Front. Pharmacol. 2014, 5:153. 10.3389/fphar.2014.00153.
25. Lessman C.A. The developing zebrafish (Danio rerio): a vertebrate model for high-throughput screening of chemical libraries. Birth Defects Res. C Embryo. Today 2011, 93(3):268-280. 10.1002/bdrc.20212.
26. Delvecchio C., Tiefenbach J., Krause H.M. The zebrafish: a powerful platform for in vivo, HTS drug discovery. Assay Drug Dev. Technol. 2011, 9(4):354-361. 10.1089/adt.2010.0346.
27. Isogai S., Horiguchi M., Weinstein B.M. The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev. Biol. 2001, 230(2):278-301. 10.1006/dbio.2000.9995.
28. Gore A.V., et al. Vascular development in the zebrafish. Cold Spring Harb. Perspect. Med. 2012, 2(5):a006684. 10.1101/cshperspect.a006684.
29. Wilkinson R.N., van Eeden F.J. The zebrafish as a model of vascular development and disease. Prog. Mol. Biol. Transl. Sci. 2014, 124:93-122. 10.1016/B978-0-12-386930-2.00005-7.
30. Lawson N.D., Weinstein B.M. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev. Biol. 2002, 248(2):307-318.
31. Kamei M., et al. Imaging blood vessels in the zebrafish. Methods Cell Biol. 2010, 100:27-54. 10.1016/B978-0-12-384892-5.00002-5.
32. Choi J., et al. FoxH1 negatively modulates flk1 gene expression and vascular formation in zebrafish. Dev. Biol. 2007, 304(2):735-744. 10.1016/j.ydbio.2007.01.023.
33. Peterson R.T., et al. Small molecule developmental screens reveal the logic and timing of vertebrate development. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(24):12965-12969. 10.1073/pnas.97.24.12965.
34. Zon L.I., Peterson R.T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 2005, 4(1):35-44. 10.1038/nrd1606.
35. Hartsock A., et al. In vivo analysis of hyaloid vasculature morphogenesis in zebrafish: a role for the lens in maturation and maintenance of the hyaloid. Dev. Biol. 2014, 394(2):327-339. 10.1016/j.ydbio.2014.07.024.
36. Kaufman R., et al. Development and origins of zebrafish ocular vasculature. BMC Dev. Biol. 2015, 15:18. 10.1186/s12861-015-0066-9.
37. Alvarez Y., et al. Genetic determinants of hyaloid and retinal vasculature in zebrafish. BMC Dev. Biol. 2007, 7:114. 10.1186/1471-213X-7-114.
38. Saint-Geniez M., D'amore P.A. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int. J. Dev. Biol. 2004, 48:1045-1058. 10.1387/ijdb.041895ms.
39. Bibliowicz J., Tittle R.K., Gross J.M. Toward a better understanding of human eye disease insights from the zebrafish, Danio rerio. Prog. Mol. Biol. Transl. Sci. 2011, 100:287-330. 10.1016/B978-0-12-384878-9.00007-8.
40. Chhetri J., Jacobson G., Gueven N. Zebrafish-on the move towards ophthalmological research. Eye (Lond) 2014, 28(4):367-380. 10.1038/eye.2014.19.
41. Cao R., et al. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PLoS One 2008, 3(7). 10.1371/journal.pone.0002748.
42. Cao Z., et al. Hypoxia-induced retinopathy model in adult zebrafish. Nat. Protoc. 2010, 5(12):1903-1910. 10.1038/nprot.2010.149.
43. Wu Y.C., et al. Hypoxia-induced retinal neovascularization in zebrafish embryos: a potential model of retinopathy of prematurity. PLoS One 2015, 10(5). 10.1371/journal.pone.0126750.
44. van Rooijen E., et al. von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish. Dis. Model. Mech. 2010, 3(5-6):343-353. 10.1242/dmm.004036.
45. Chew E.Y. Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations. Trans. Am. Ophthalmol. Soc. 2005, 103:495-511.
46. Collin R.W., et al. ZNF408 is mutated in familial exudative vitreoretinopathy and is crucial for the development of zebrafish retinal vasculature. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(24):9856-9861. 10.1073/pnas.1220864110.
47. Gleeson M., Connaughton V., Arneson L.S. Induction of hyperglycaemia in zebrafish (Danio rerio) leads to morphological changes in the retina. Acta Diabetol. 2007, 44(3):157-163. 10.1007/s00592-007-0257-3.
48. Jung S.H., et al. High glucose-induced changes in hyaloid-retinal vessels during early ocular development of zebrafish: a short-term animal model of diabetic retinopathy. Br. J. Pharmacol. 2015, 10.1111/bph.13279.
49. Alvarez Y., et al. Selective inhibition of retinal angiogenesis by targeting PI3 kinase. PLoS One 2009, 4(11). 10.1371/journal.pone.0007867.
50. Reynolds A.L., et al. Phenotype-based discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a novel regulator of ocular angiogenesis. J. Biol. Chem. 2016, 291(14):7242-7255. 10.1074/jbc.M115.710665.